Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Pharmacokinetics
Erschienen in: Clinical Pharmacokinetics 8/2014

01.08.2014 | Review Article

Clinical Pharmacology of Deferasirox

verfasst von: Chiaki Tanaka

Erschienen in: Clinical Pharmacokinetics | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Iron accumulation is a consequence of regular red cell transfusions, and can occur as a result of ineffective erythropoiesis secondary to increased intestinal iron absorption, in patients with various anemias. Without appropriate treatment, iron overload can lead to increased morbidity and mortality. Deferasirox is an oral iron chelator effective for reduction of body iron in iron-overloaded patients with transfusion-dependent anemias and non-transfusion-dependent thalassemia, with a well-established safety profile. This review summarizes the clinical pharmacokinetics, pharmacodynamics, and drug–drug interaction profile of deferasirox, and the claims supporting once-daily dosing for effective chelation. Sustained labile plasma iron suppression is observed with no rebound between doses, protecting organs from potential tissue damage. Increased iron excretion positively correlates with increased deferasirox exposure; to optimize iron removal transfusional iron intake, body iron burden and safety parameters should also be considered. Deferasirox dispersible tablets should be taken ≥30 min before food due to an effect of food on bioavailability. Dosing is consistent across pediatric and adult patients and there is no ethnic sensitivity. Dose adjustment is required for patients with hepatic impairment and may be considered upon coadministration with strong uridine diphosphate glucuronosyltransferase inducers or bile acid sequestrants (coadministration should be avoided where possible), and patients should be monitored upon coadministration with cytochrome P450 (CYP) 3A4/5, CYP2C8, or CYP1A2 substrates. Coadministration with hydroxyurea, a fetal hemoglobin modulator, does not appear to impact deferasirox pharmacokinetics. In summary, a substantial body of clinical and pharmacokinetic data are available for deferasirox to guide its optimal use in multiple patient populations and clinical circumstances.
Literatur
1.
2.
3.
4.
Smith-Whitley K, Thompson AA. Indications and complications of transfusions in sickle cell disease. Pediatr Blood Cancer. 2012;59:358–64.PubMedCrossRef
5.
Kurtin SE. Myelodysplastic syndromes: diagnosis, treatment planning, and clinical management. Oncology (Williston Park). 2007;21:41–8.
6.
Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in β-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007;109:5027–35.PubMedCentralPubMedCrossRef
7.
Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β-thalassemia intermedia. Haematologica. 2011;96:1605–12.PubMedCentralPubMedCrossRef
8.
Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115:1886–92.PubMedCrossRef
9.
10.
Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107:3455–62.PubMedCrossRef
11.
Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. 2010;95:557–66.PubMedCentralPubMedCrossRef
12.
Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood. 2011;118:884–93.PubMedCrossRef
13.
Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–80.PubMed
14.
Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168–76.PubMedCentralPubMed
15.
Taher AT, Porter J, Viprakasit V, et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120:970–7.PubMedCrossRef
16.
Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92:1485–93.PubMedCentralPubMedCrossRef
17.
Vichinsky E, Coates TD, Thompson AA, et al. Long-term efficacy and safety of deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD). Blood. 2007;110(11):abst 3395.
18.
Pennell D, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica. 2012;97:842–8.PubMedCentralPubMedCrossRef
19.
Pennell DJ, Porter JB, Piga A, et al. A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). Blood. 2014;123:1447–54.PubMedCentralPubMed
20.
Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. Eur J Haematol. 2009;82:454–7.PubMedCentralPubMedCrossRef
21.
al Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403–8.PubMedCrossRef
22.
Cabantchik ZI, Breuer W, Zanninelli G, et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–87.PubMedCrossRef
23.
24.
Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9:2391–402.PubMedCrossRef
25.
McLeod C, Fleeman N, Kirkham J, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess. 2009;13:iii–iv, ix–xi, 1–121.
26.
Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003;10:1065–76.PubMedCrossRef
27.
Deferasirox. In: O’Neil MJ, editor. The Merck Index—an encyclopedia of chemicals, drugs, and biologicals. Whitehouse Station: Merck and Co., Inc.; 2006. p. 483.
28.
Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp Med Biol. 2002;509:185–203.PubMedCrossRef
29.
Sechaud R, Dutreix C, Balez S, et al. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther. 2008;46:102–8.PubMedCrossRef
30.
31.
Heinz U, Hegetschweiler K, Acklin P, et al. 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel, efficient and selective iron(iii) complexing agent. Angew Chem Int Ed Engl. 1999;38:2568–70.PubMedCrossRef
32.
Rouan MC, Marfil F, Mangoni P, et al. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001;755:203–13.PubMedCrossRef
33.
Skerjanec A, Wang J, Maren K, et al. Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol. 2010;50:205–13.PubMedCrossRef
34.
Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597–602.PubMedCrossRef
35.
Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191–201.PubMedCrossRef
36.
Weiss HM, Fresneau M, Camenisch GP, et al. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2, for rat, marmoset, rabbit, mouse, dog, and human. Drug Metab Dispos. 2006;34:971–5.PubMed
37.
Sechaud R, Robeva A, Belleli R, et al. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol. 2008;48:919–25.PubMedCrossRef
38.
Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol. 2003;43:565–72.PubMedCrossRef
39.
Galanello R, Piga A, Cappellini MD, et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol. 2008;48:428–35.PubMedCrossRef
40.
Goldberg SL, Giardina PJ, Chirnomas D, et al. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013;60:1507–12.PubMedCrossRef
41.
Bruin GJ, Faller T, Wiegand H, et al. Pharmacokinetics, distribution, metabolism and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos. 2008;36:2523–38.PubMedCrossRef
42.
Waldmeier F, Bruin GJ, Glaenzel U, et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos. 2010;38:808–16.PubMedCrossRef
43.
Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002;66:185–200.PubMedCrossRef
44.
Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84:417–23.PubMedCrossRef
45.
Sechaud R, Dumortier T, Balez S. Deferasirox does not induce QT/QTc-prolongation in healthy subjects. Int J Clin Pharmacol Ther. 2009;47:321–7.PubMedCrossRef
46.
Miyazawa K, Ohyashiki K, Urabe A, et al. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. Int J Hematol. 2008;88:73–81.PubMedCrossRef
47.
Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica. 2006;91:1343–51.PubMed
48.
Vichinsky E, El-Beshlawy A, Alzoebie A, et al. Interim safety and effectiveness results from a 5-year observational study of deferasirox in pediatric patients aged 2–<6 years at enrollment [abstract]. Blood. 2012;120(21):abst 2125.
49.
Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin. 2009;33(Suppl 1):S46–57.PubMedCrossRef
50.
Mallat ME, Sharara AI. Treatment and prevention of hepatitis B and C in thalassemia. Hemoglobin. 2009;33(Suppl 1):S139–44.PubMedCrossRef
51.
Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant. 2014;29:255–9.PubMedCrossRef
52.
Maker GL, Siva B, Batty KT, et al. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology (Carlton). 2013;18:188–93.CrossRef
53.
Sechaud R, Robeva A, Belleli R, et al. Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. Int J Clin Pharmacol Ther. 2008;46:519–26.PubMedCrossRef
54.
Rolan PE. Plasma protein binding displacement interactions—why are they still regarded as clinically important? Br J Clin Pharmacol. 1994;37:125–8.PubMedCentralPubMedCrossRef
55.
Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf. 1995;12:227–33.PubMedCrossRef
56.
Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115–21.PubMedCrossRef
57.
58.
Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663–72.PubMedCentralPubMedCrossRef
59.
Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317–22.PubMedCrossRef
60.
Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol. 1998;20:26–31.PubMedCrossRef
61.
Voskaridou E, Bilalis A, Christoulas D, et al. Prolonged administration of hydroxyurea reduces morbidity and mortality in adult patients with sickle-cell syndromes: final analysis of a 17-year, single center, trial [abstract no. 1079]. Haematologica. 2009;94(Suppl 2):435.
62.
Vichinsky E, Torres M, Minniti CP, et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol. 2013;88:1068–73.PubMedCrossRef
63.
Sweiss K, Patel P, Rondelli D. Deferasirox increases BU blood concentrations. Bone Marrow Transplant. 2012;47:315–6.PubMedCrossRef
64.
Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357–62.PubMedCrossRef
65.
Hernando D, Levin YS, Sirlin CB, et al. Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging. Epub 2014 Mar 3.
66.
Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program. 2009;215–21.
67.
Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739–61.PubMed
68.
Taher A, Elalfy MS, Al Zir K, et al. Importance of optimal dosing >30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol. 2011;87:355–65.PubMedCentralPubMedCrossRef
69.
Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009;114:4009–13.PubMedCentralPubMedCrossRef
70.
Chang HH, Lu MY, Liao YM, et al. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia. Pediatr Blood Cancer. 2011;56:420–4.PubMedCrossRef
71.
Pongtanakul B, Viprakasit V. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose. Blood Cells Mol Dis. 2013;51:96–7.PubMedCrossRef
72.
Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567–73.PubMedCrossRef
73.
Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26–36.PubMedCrossRef
74.
Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051–2.PubMedCrossRef
75.
Porter JB, Evangeli M, El-Beshlawy A. The challenges of adherence and persistence with iron chelation therapy. Int J Hematol. 2011;94:453–60.PubMedCrossRef
76.
Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752–9.PubMedCentralPubMedCrossRef
77.
Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501–8.PubMedCentralPubMedCrossRef
78.
Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154:387–97.PubMedCentralPubMedCrossRef
79.
Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115:2364–71.PubMedCrossRef
80.
Piga A, Fracchia S, Lai ME, et al. Two-year renal hemodynamic effects of deferasirox in patients with transfusion-dependent β-thalassemia [abstract no. 3257]. Blood. 2012;120(21):3257.
Metadaten
Titel
Clinical Pharmacology of Deferasirox
verfasst von
Chiaki Tanaka
Publikationsdatum
01.08.2014
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 8/2014
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-014-0151-4

Weitere Artikel der Ausgabe 8/2014

Clinical Pharmacokinetics 8/2014 Zur Ausgabe

Original Research Article

Pharmacokinetics of Orally Administered Duloxetine in Children and Adolescents with Major Depressive Disorder

Short Communication

Why Dried Blood Spots Are an Ideal Tool for CYP1A2 Phenotyping

Original Research Article

Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI ≥40 kg/m2) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring

Original Research Article

Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer

Current Opinion

Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved

Review Article

A Comprehensive Review on the Pharmacokinetics of Antibiotics in Interstitial Fluid Spaces in Humans: Implications on Dosing and Clinical Pharmacokinetic Monitoring